Immuneering Corp
IMRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMRX
Immuneering Corp (IMRX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with its lead product candidate atebimetinib currently in Phase 2/3 trials.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$322.8M
Cash Runway
13.9 moLead Asset
atebimetinib (Phase 3)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials · 3 catalysts for Immuneering Corp.
Immuneering Corp (IMRX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with its lead product candidate atebimetinib currently in Phase 2/3 trials.
- Lead product candidate atebimetinib is being evaluated in a Phase 2/3 registrational trial for first-line pancreatic cancer [sec_mda · as of 2026-03-06].
- As of June 30, 2026, the company had an accumulated deficit of approximately $311.1 million and cash, cash equivalents, and marketable securities of approximately $182.7 million [sec_mda · as of 2026-08-05].
- Latest reported financials (as of 2026-06-30) show cash & equivalents of $41.3M, net income of -$17.3M, and shareholders' equity of $218.5M [sec].
- The company has no internally developed products approved for sale and does not expect to generate product revenue until successful development and regulatory approval [sec_mda · as of 2026-08-05].
What works
- Atebimetinib is advancing in a registrational trial for first-line pancreatic cancer, a large unmet medical need [sec_mda · as of 2026-03-06].
- The company has a substantial cash position of approximately $182.7 million as of June 30, 2026, which may support ongoing development activities [sec_mda · as of 2026-08-05].
- Multiple upcoming catalysts include Phase 2 topline data for atebimetinib in 2026 and a Phase 3 topline readout in 2029 [catalyst_timeline].
What to weigh
- The company has an accumulated deficit of $311.1 million as of June 30, 2026, reflecting a history of operating losses [sec_mda · as of 2026-08-05].
- No internally developed products have been approved for sale, and the company expects to incur significant commercialization expenses if approval is obtained [sec_mda · as of 2026-08-05].
- Expenses are expected to increase substantially as clinical trials advance, and the company may need additional financing to fund operations [sec_mda · as of 2026-03-06].
From the filings
Quoted directly from source documents.
Accumulated deficit and cash position as of June 30, 2026
“June 30, 2026, we had an accumulated deficit of approximately $311.1 million and approximately $182.7 million in cash, cash equivalents and marketable securities.”
SEC MD&A · August 5, 2026
No internally developed products approved for sale
“We have not had any internally developed products approved for sale.”
SEC MD&A · August 5, 2026
Planned registrational trial for atebimetinib in pancreatic cancer
“our planned registrational trial of atebimetinib in combination with mGnP in first-line pancreatic cancer”
SEC MD&A · March 6, 2026
Expectation of increased expenses with clinical advancement
“We expect that our expenses will increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development.”
SEC MD&A · March 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · atebimetinib — Phase 2 Readout: atebimetinib — Topline data from the Phase 2 portion of the atebimetinib trial will be reported, providing initial efficacy and safety signals.
- 2027-12-31 · Phase2_Topline · atebimetinib in combination with libtayo — Phase 2 Readout: atebimetinib in combination with libtayo — Topline data from the Phase 2 trial of atebimetinib combined with libtayo will be released, assessing combination therapy potential.
- 2029-02-01 · Phase3_Topline · atebimetinib — Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine — Topline results from the Phase 3 registrational trial of atebimetinib plus modified gemcitabine in first-line pancreatic cancer are expected.
Risks & what to watch (4)›
Key risks
- No approved products — No internally developed products have been approved for sale, and revenue generation is uncertain [sec_mda · as of 2026-08-05].
- Significant accumulated deficit — Accumulated deficit of $311.1M as of June 30, 2026, indicating sustained losses [sec_mda · as of 2026-08-05].
- Clinical trial risks — Atebimetinib trials may fail to meet endpoints, delaying or preventing regulatory approval [sec_mda · as of 2026-03-06].
- Need for additional capital — Expenses are expected to increase, and the company may need to raise funds through equity or debt [sec_mda · as of 2026-03-06].
What to watch
- Phase 2 topline data for atebimetinib expected by December 31, 2026 [catalyst_timeline].
- Phase 2 topline data for atebimetinib in combination with libtayo expected by December 31, 2027 [catalyst_timeline].
- Phase 3 topline readout for atebimetinib in combination with modified gemcitabine expected by February 1, 2029 [catalyst_timeline].
- Cash runway and any additional financing activities as clinical programs advance [sec_mda · as of 2026-08-05].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Immuneering Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immuneering Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
13.9 months
D/E 0.06 · 0% dilution
Lead: Phase 3
4 candidates
3 upcoming, next in ~123d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
92
Total value held
$128.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,697,938 | $51.1M |
| vanguard capital management llc | 2,288,341 | $12.1M |
| marshall wace, llp | 1,996,585 | $10.5M |
| blackrock, inc. | 1,507,258 | $7.9M |
| millennium management llc | 1,102,712 | $5.8M |
| geode capital management, llc | 637,944 | $3.4M |
| citadel advisors llc | 529,078 | $2.8M |
| connor, clark & lunn investment management ltd. | 400,363 | $2.1M |
| summit financial, llc | 376,749 | $2.0M |
| ubs group ag | 376,284 | $2.0M |
Showing top 10 of 92 institutional holders of Immuneering Corp. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 19.4%
- Days to cover
- 12.4
- Shares short
- 9,500,184
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immuneering Corp?
Immuneering Corp (IMRX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with its lead product candidate atebimetinib currently in Phase 2/3 trials.
What is Immuneering Corp's lead drug candidate?
Immuneering Corp's most advanced tracked candidate is atebimetinib (Phase 3) for Pancreatic Cancer.
What is Immuneering Corp's next catalyst?
Immuneering Corp's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: atebimetinib" — expected December 31, 2026.
Who is the CEO of Immuneering Corp?
Dr. Benjamin J. Zeskind M.B.A., Ph.D. is the chief executive officer of Immuneering Corp (IMRX).
Where is Immuneering Corp headquartered?
Immuneering Corp (IMRX) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.